epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Emverm
    mebendazole
  • remove Uribel Tabs
    methenamine/ benzoic acid/ phenyl salicylate/ methylene blue/ hyoscyamine
  • remove Virtussin DAC
    codeine/ pseudoephedrine/ guaifenesin

multicheck MultiCheck Results - 3 Interactions

Smiley face Smiley face

Contraindicated

Smiley face Smiley face Uribel Tabs (methenamine/ benzoic acid/ phenyl salicylate/ methylene blue/ hyoscyamine) + Virtussin DAC (codeine/ pseudoephedrine/ guaifenesin)

Contraindicated


methylene blue oral + codeine

contraindicated w/in 14 days of methylene blue use; if urgent use, consider alternative, incl. buprenorphine or oxymorphone: combo may incr. risk of respiratory depression, serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

Avoid/Use Alternative


hyoscyamine + codeine

avoid combo if antitussive use; otherwise, monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe constipation, paralytic ileus, urinary retention (additive effects)

Monitor/Modify Tx


hyoscyamine + pseudoephedrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

Additional Considerations

Smiley face Smiley face hyoscyamine in Uribel Tabs

caution advised with concurrent oral drugs requiring rapid onset; hyoscyamine delays gastric emptying, may alter absorption of concomitant oral drugs

Smiley face Smiley face codeine in Virtussin DAC

consider prescribing an opioid overdose reversal agent, especially with concomitant CNS depressant use

add MAO inhibitor to Interaction Check if recent (14 days) use

Smiley face Smiley face pseudoephedrine in Virtussin DAC

add MAO inhibitor to Interaction Check if recent (14 days) use

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information